SCHEMBL14360697

SCHEMBL14360697

Cc1ccc(-c2ccc(C)n2C)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GFER P55789 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
HSF1 Q00613 3/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
KDM4E B2RXH2 3/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633835 0.75 CHRM2 (0.37) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL29764 0.71 NPC1 (0.52) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12279046 0.69 GRIN1 (0.33) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL27560769 0.69 KDM4E (0.45) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12982161 0.69 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL11997754 0.69 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12982405 0.69 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL120939 0.69 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12170048 0.69 NPC1 (0.50) NPC1MAPTALDH1A1HSD17B10GFER
SCHEMBL12929392 0.68 RAB9A (0.39) NPC1MAPTALDH1A1HSD17B10GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed
US-20070275956-A1 Novel Heterocyclic Compounds CADILA HEALTHCARE LIMITED (IN) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275956-A1 Novel Heterocyclic Compounds CYP46A1, DHCR7, NPC1L1 NPC1 11/4885MAPT 162/4885ALDH1A1 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.